Aurinia Pharmaceuticals: EC Approved Lupkynis for Active Lupus Nephritis

By Colin Kellaher

Aurinia Pharmaceuticals Inc. on Monday said the European Commission approved Lupkynis to treat adults with active lupus nephritis, triggering a $30 million milestone payment from partner Otsuka Pharmaceutical Co.

The Victoria, British Columbia, biopharmaceutical company said Lupkynis is the first oral medicine approved in both the U.S. and Europe for adults with active lupus nephritis, a serious complication of the inflammatory disease systemic lupus erythematosus.

The U.S. Food and Drug Administration approved a Lupkinis combination regimen early last year.

Aurinia and Otsuka inked a collaboration and licensing agreement in December 2020 to develop and commercialize the drug in the EU and several other countries. Aurinia said it will recognize the EC approval-related milestone payment as revenue in the third quarter.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

September 19, 2022 11:49 ET (15:49 GMT)

Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Mar 2024 to Apr 2024